Tumoral angiogenesis and breast cancer |
| |
Authors: | Parham Khosravi Shahi Alicia Soria Lovelle Gumersindo Pérez Manga |
| |
Institution: | 1. Servicio de Oncología Médica, Hospital General Universitario Gregorio Mara?ón, C/ Dr. Esquerdo, 46, ES-28007, Madrid, Spain
|
| |
Abstract: | Breast cancer (BC) is the most common neoplasm in women in Western countries. Tumoral angiogenesis (TA) is essential for the
growth and spread of BC cells. There are at least 6 different angiogenic growth factors associated with TA in BC. The major
mediator of TA is vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glycoprotein. VEGF signals through
VEGF receptor-2 (VEGFR-2), the major VEGF signalling receptor that mediates sprouting angiogenesis. Recently, different antiangiogenic
agents have shown efficacy in the treatment of advanced BC. Bevacizumab, a humanised monoclonal antibody against VEGF, in
combination with taxanes improves progression-free survival and overall response rate in first-line therapy. Other new antiangiogenic
agents, called multi-kinase inhibitors (sunitinib and pazopanib), are under investigation. Finally, a schedule of treatment
called metronomic chemotherapy, with antiangiogenic activity, has also demonstrated efficacy in the treatment of advanced
BC. |
| |
Keywords: | VEGF Sunitinib Bevacizumab Metronomic chemotherapy Pazopanib |
本文献已被 SpringerLink 等数据库收录! |
|